Burjeel Holdings reported unaudited preliminary results for the year ended December 31, 2025, posting revenue of AED 5.5 billion, up 9.8% year-on-year, as total patient visits exceeded 7 million, an 8.4% increase. Growth was supported by specialized services aligned with local demand and the ramp-up of newly launched facilities.
EBITDA rose 19.9% to AED 1.09 billion, while the margin expanded to 19.8% from 18.1% in 2024. Consequently, net profit increased 39.5% to AED 503 million, with the net margin improving to 9.1%. In the fourth quarter alone, net profit surged 159.9% year-on-year, reflecting operating leverage and cost discipline.
Inpatient volumes grew 11.7%, driven by oncology, cardiology, gastroenterology and orthopedics. Meanwhile, outpatient footfall rose 8.3%, supported by expansion of the ambulatory network.
Dr. Shamsheer Vayalil said: “2025 was a year of strong momentum for Burjeel Holdings… we are well positioned to deliver sustainable long-term value for shareholders while elevating access to high-quality healthcare.”
